U.S. flag

An official website of the United States government

NM_000260.4(MYO7A):c.4972C>T (p.Gln1658Ter) AND not provided

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Jun 13, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001882614.3

Allele description [Variation Report for NM_000260.4(MYO7A):c.4972C>T (p.Gln1658Ter)]

NM_000260.4(MYO7A):c.4972C>T (p.Gln1658Ter)

Gene:
MYO7A:myosin VIIA [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
11q13.5
Genomic location:
Preferred name:
NM_000260.4(MYO7A):c.4972C>T (p.Gln1658Ter)
HGVS:
  • NC_000011.10:g.77201567C>T
  • NG_009086.2:g.78322C>T
  • NM_000260.4:c.4972C>TMANE SELECT
  • NM_001127180.2:c.4858C>T
  • NM_001369365.1:c.4825C>T
  • NP_000251.3:p.Gln1658Ter
  • NP_001120652.1:p.Gln1620Ter
  • NP_001356294.1:p.Gln1609Ter
  • LRG_1420t1:c.4972C>T
  • LRG_1420:g.78322C>T
  • LRG_1420p1:p.Gln1658Ter
  • NC_000011.9:g.76912612C>T
Protein change:
Q1609*
Links:
dbSNP: rs1401619267
NCBI 1000 Genomes Browser:
rs1401619267
Molecular consequence:
  • NM_000260.4:c.4972C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001127180.2:c.4858C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001369365.1:c.4825C>T - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002190845Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Jun 13, 2022)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Myosin VIIA mutation screening in 189 Usher syndrome type 1 patients.

Weston MD, Kelley PM, Overbeck LD, Wagenaar M, Orten DJ, Hasson T, Chen ZY, Corey D, Mooseker M, Sumegi J, Cremers C, Moller C, Jacobson SG, Gorin MB, Kimberling WJ.

Am J Hum Genet. 1996 Nov;59(5):1074-83.

PubMed [citation]
PMID:
8900236
PMCID:
PMC1914835

Targeted next generation sequencing for molecular diagnosis of Usher syndrome.

Aparisi MJ, Aller E, Fuster-García C, García-García G, Rodrigo R, Vázquez-Manrique RP, Blanco-Kelly F, Ayuso C, Roux AF, Jaijo T, Millán JM.

Orphanet J Rare Dis. 2014 Nov 18;9:168. doi: 10.1186/s13023-014-0168-7.

PubMed [citation]
PMID:
25404053
PMCID:
PMC4245769
See all PubMed Citations (3)

Details of each submission

From Invitae, SCV002190845.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with MYO7A-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gln1658*) in the MYO7A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYO7A are known to be pathogenic (PMID: 8900236, 25404053).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Feb 28, 2024